KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CareDx (CDNA) Cost of Revenue: 2013-2025

Historic Cost of Revenue for CareDx (CDNA) over the last 12 years, with Sep 2025 value amounting to $24.4 million.

  • CareDx's Cost of Revenue rose 23.47% to $24.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $92.8 million, marking a year-over-year increase of 15.09%. This contributed to the annual value of $81.7 million for FY2024, which is 1.94% down from last year.
  • Per CareDx's latest filing, its Cost of Revenue stood at $24.4 million for Q3 2025, which was up 0.70% from $24.3 million recorded in Q2 2025.
  • In the past 5 years, CareDx's Cost of Revenue ranged from a high of $26.9 million in Q2 2022 and a low of $15.5 million during Q1 2021.
  • In the last 3 years, CareDx's Cost of Revenue had a median value of $21.1 million in 2024 and averaged $21.5 million.
  • Per our database at Business Quant, CareDx's Cost of Revenue surged by 61.52% in 2021 and then declined by 19.74% in 2023.
  • Quarterly analysis of 5 years shows CareDx's Cost of Revenue stood at $20.8 million in 2021, then rose by 13.66% to $23.7 million in 2022, then declined by 15.50% to $20.0 million in 2023, then grew by 5.43% to $21.1 million in 2024, then rose by 23.47% to $24.4 million in 2025.
  • Its last three reported values are $24.4 million in Q3 2025, $24.3 million for Q2 2025, and $23.0 million during Q1 2025.